Xiamen Innovax Biotech Co., Ltd. (“IX”), founded in 2005, is one of China’s leading innovative vaccine companies engaged in the research, development, manufacturing, and commercialization of human vaccines.
Provide high quality and affordable vaccines to improve human well-being
IX has established partnerships with healthcare institutions, government agencies, and international organizations across more than 30 countries and regions, accelerating the global reach of high-quality vaccines and empowering local vaccine manufacturing via technology transfer.
Angola
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：1 dose
Target Population - Sex：Female
Current Timing of Vaccine Doses：9-12 years
Bangladesh
Burkina Faso
Belarus
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：2 doses
Target Population - Sex：Female
Current Timing of Vaccine Doses：11-14 years
Burundi
China
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：2 doses
Target Population - Sex：Female
Current Timing of Vaccine Doses：13 years
Cambodia
Cuba
Cuba implemented Cecolin vaccination to protect against human papillomavirus (HPV)
DR Congo
Egypt
Ethiopia
Ghana
Guatemala
India
Hecolin was successfully launched in India to help prevent hepatitis E virus infection
Indonesia
Kazakhstan
Kenya
Madagascar
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：1 dose
Target Population - Sex：Female
Current Timing of Vaccine Doses：9-14 years
Mali
Mexico
Morocco
Myanmar
Nepal
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：1 dose
Target Population - Sex：Female
Current Timing of Vaccine Doses：10-14 years
Nicaragua
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：2 doses
Target Population - Sex：Male and Female
Current Timing of Vaccine Doses：12-14 years
Niger
Nigeria
Pakistan
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：1 dose
Target Population - Sex：Female
Current Timing of Vaccine Doses：9-14 years during campaign
Pakistan
Hecolin is approved and has been used in Pakistan, primarily in targeted or outbreak-related vaccination settings
South Sudan
Market Type：Mass Campagin
Current or Planned Formulation：Hecolin (HEV)
Current Dosing Schedule：following PIL
Thailand
Thailand used Cecolin for National EPI and further expanded to 11-20 years old girls.
Tunisia
Market Type：EPI
Current or Planned Formulation：Cecolin (HPV-2)
Current Dosing Schedule：1 dose
Target Population - Sex：Female
Current Timing of Vaccine Doses：12 years
This website is intended for a broad scientific audience and may contain information about products or indications that are not licensed, approved, or available in your country or region. Prescribing information and other medical information may vary between countries or regions.For more information, please visit www.xiameninnovax.com
闽公网安备 35020502000554号
Terms of Use
Privacy Policy
